Life Sciences and Biotechnology
-
European Commission
Abstract
Introduction
In January 2002, the Commission adopted a Strategy for Europe on Life Sciences and Biotechnology, consisting of two parts – policy orientations and a 30-point plan to transform policy into action. It sets out what is needed from the Commission and the other European Institutions, while also recommending actions for other public and private stakeholders.
The Commission intends to report regularly on the progress made. The Commission adopted its second progress report on 7 April 2004, which highlighted the progress made but also pointed out delays in some areas.
This Communication is the third such response. As last year, this report is supported by a Commission Staff Working Paper, which provides detailed information on the implementation of the action plan.
Walter de Gruyter GmbH & Co. KG
Articles in the same Issue
- Editorial
- Biosafety Regulation Trends in Southern and Southeastern Asia
- Property in a Human Body: A Common Law Approach
- Pharmacogenomics: An In-House Advantage?
- The German Way of Dealing with “The Tragedy of the Anticommons” – Purpose-Bound Protection for Product Patents on Genetic Information in Germany
- Pharmacogenomics and Data Protection
- Development and Implications of Patent Law
- Life Sciences and Biotechnology
- Declaration on Human Cloning
- Gene Therapy in PR China: Regulations and Ethical Concerns
- Biotechnological Potential of Marine Sponges and their Associated Bacteria as Producers of New Pharmaceuticals (Part I)
Articles in the same Issue
- Editorial
- Biosafety Regulation Trends in Southern and Southeastern Asia
- Property in a Human Body: A Common Law Approach
- Pharmacogenomics: An In-House Advantage?
- The German Way of Dealing with “The Tragedy of the Anticommons” – Purpose-Bound Protection for Product Patents on Genetic Information in Germany
- Pharmacogenomics and Data Protection
- Development and Implications of Patent Law
- Life Sciences and Biotechnology
- Declaration on Human Cloning
- Gene Therapy in PR China: Regulations and Ethical Concerns
- Biotechnological Potential of Marine Sponges and their Associated Bacteria as Producers of New Pharmaceuticals (Part I)
